Wanbangde Pharmaceutical Holding Group Co Ltd
Wanbangde Pharmaceutical Holding Group Co., Ltd. engages in the research and development, production, and sale of traditional Chinese medicine, chemical raw materials, and chemical preparations in China and internationally. The company operates through two segments, the Pharmaceutical Business and the Medical Device Business. It offers drugs products used to treat cardiovascular and cerebrovascul… Read more
Wanbangde Pharmaceutical Holding Group Co Ltd (002082) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.78 Billion CNY
Based on the latest financial reports, Wanbangde Pharmaceutical Holding Group Co Ltd (002082) has total liabilities worth CN¥1.78 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Wanbangde Pharmaceutical Holding Group Co Ltd - Total Liabilities Trend (2003–2024)
This chart illustrates how Wanbangde Pharmaceutical Holding Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Wanbangde Pharmaceutical Holding Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Wanbangde Pharmaceutical Holding Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Foxsemicon Integrated Technology Inc
TW:3413
|
Taiwan | NT$9.49 Billion |
|
ACEA S.p.A
OTCGREY:ACEJF
|
USA | $9.65 Billion |
|
ATOSS Software SE
F:AOF
|
Germany | €58.77 Million |
|
Electricity Gnrtng NVtg
OTCGREY:EYUUF
|
USA | $124.04 Billion |
|
Autobio Diagnostics Co Ltd
SHG:603658
|
China | CN¥2.88 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Wanbangde Pharmaceutical Holding Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.39 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Wanbangde Pharmaceutical Holding Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Wanbangde Pharmaceutical Holding Group Co Ltd (2003–2024)
The table below shows the annual total liabilities of Wanbangde Pharmaceutical Holding Group Co Ltd from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.57 Billion | +2.18% |
| 2023-12-31 | CN¥1.54 Billion | +10.09% |
| 2022-12-31 | CN¥1.40 Billion | -14.15% |
| 2021-12-31 | CN¥1.63 Billion | -41.99% |
| 2020-12-31 | CN¥2.80 Billion | +48.47% |
| 2019-12-31 | CN¥1.89 Billion | +68.37% |
| 2018-12-31 | CN¥1.12 Billion | +125.90% |
| 2017-12-31 | CN¥496.58 Million | +89.65% |
| 2016-12-31 | CN¥261.85 Million | -3.12% |
| 2015-12-31 | CN¥270.28 Million | +6.12% |
| 2014-12-31 | CN¥254.69 Million | -29.46% |
| 2013-12-31 | CN¥361.07 Million | -23.03% |
| 2012-12-31 | CN¥469.09 Million | +19.60% |
| 2011-12-31 | CN¥392.22 Million | +3.09% |
| 2010-12-31 | CN¥380.46 Million | +23.77% |
| 2009-12-31 | CN¥307.39 Million | -0.67% |
| 2008-12-31 | CN¥309.46 Million | -39.62% |
| 2007-12-31 | CN¥512.51 Million | +3.78% |
| 2006-12-31 | CN¥493.85 Million | -2.95% |
| 2005-12-31 | CN¥508.84 Million | +81.42% |
| 2004-12-31 | CN¥280.48 Million | +72.03% |
| 2003-12-31 | CN¥163.05 Million | -- |